
EMA Releases Guidelines on Advanced Therapies
The new guidelines discuss GMPs and patient protection specific to advanced therapy medicinal products.
On Nov. 24, 2017, the European Medicines Agency (EMA)
The guidelines are part of a
ATMPs are treatments based on gene or cells and can offer new options for patients with severe, untreatable, or chronic conditions.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.